AVCR Avricore Health

Avricore Health Recognized in Deloitte’s 2024 Technology Fast 50™ Companies to Watch

Avricore Health Recognized in Deloitte’s 2024 Technology Fast 50™ Companies to Watch

VANCOUVER, British Columbia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSX-V: AVCR), a leader in pharmacy-based health technology solutions, proudly announces its placement in Deloitte Canada’s 2024 Technology Fast 50™ Companies-to-Watch category, securing the 8th position with an impressive growth rate of 2738%. This award acknowledges Avricore’s pioneering work in real-time data and health testing through its platform, HealthTab™, which empowers pharmacies to support patient health outcomes effectively.

“We are thrilled to be recognized in Deloitte’s Fast 50,” said Hector Bremner, CEO of Avricore “This is a testament to our team’s dedication to advancing accessible health solutions and strengthening pharmacy services in Canada.”

The Deloitte Technology Fast 50™ program highlights Canada’s innovation leaders driving growth and transformation across technology sectors. The award amplifies Avricore’s commitment to delivering exceptional, patient-centered care and advancing digital health solutions.

HealthTab™ Market Fast Facts

  • Point of Care Testing Market to reach $93.21 Billion USD in 2030 ()
  • Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed ()
  • Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes ()
  • Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it’s only after a heart attack they are diagnosed. ()
  • There are more than 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

About HealthTab™

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API. 

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab™, a wholly owned subsidiary, the Company’s mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

Contact:

Avricore Health Inc.

Hector Bremner, CEO 604-773-8943



Cautionary Note Regarding Forward-Looking Statements

Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy



EN
06/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avricore Health

 PRESS RELEASE

AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on tr...

AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on track VANCOUVER, British Columbia, May 01, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) reports on its year end 2024 and In the year ended December 31, 2024 revenue increased by 37% year over year to $4,785,711 and gross profit increased by 56% to $1,880,306.In the three months ended December 31, 2024 revenue increased by 5% year over year to $1,421,076 and gross profit increased by 18% to $589,930. “Launching and expanding HealthTab™ in North East ...

 PRESS RELEASE

HealthTab™ and Patients Know Best® Bring Pharmacy-Based Blood Test Res...

HealthTab™ and Patients Know Best® Bring Pharmacy-Based Blood Test Results to Millions in UK VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) today announced its successful integration of HealthTab™ the Company’s cloud-connected, pharmacy-based platform for testing and health data management, with Patients Know Best (PKB), the UK’s leading patient personal health record (PHR). The new partnership enables a seamless connection between real-time diagnostic results from pharmacy point-of...

 PRESS RELEASE

Avricore Health Corporate Update: Effective Plan, Resources Result in ...

Avricore Health Corporate Update: Effective Plan, Resources Result in Success VANCOUVER, British Columbia, Nov. 29, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) reports on its third quarter results for 2024 where the Company continues to see rising revenues and profitability. In the nine months ended September 30, 2024, revenue increased by 58% year over year to $3,364,635 and gross profit increased by 84% to $1,290,357.In the three months ended September 30, 2024, revenue increased by 25% year over year to $1,195,122 and gross profit increase...

 PRESS RELEASE

Avricore Health Refocuses Strategy to Unlock Growth Potential

Avricore Health Refocuses Strategy to Unlock Growth Potential VANCOUVER, British Columbia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSX-V: AVCR) ("Avricore" or the "Company"), a leader in pharmacy-based point-of-care testing solutions, today announces a strategic shift to increase its focus on the rapidly expanding UK healthcare market and begin concluding its Canadian pharmacy partnership with Shoppers Drug Mart. This shift in market development builds on the UCL Partners of its rapid cholesterol initiative in community pharmacies in North East London. Key Business Upda...

 PRESS RELEASE

Avricore Health Recognized in Deloitte’s 2024 Technology Fast 50™ Comp...

Avricore Health Recognized in Deloitte’s 2024 Technology Fast 50™ Companies to Watch VANCOUVER, British Columbia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSX-V: AVCR), a leader in pharmacy-based health technology solutions, proudly announces its placement in Deloitte Canada’s 2024 Technology Fast 50™ Companies-to-Watch category, securing the 8th position with an impressive growth rate of 2738%. This award acknowledges Avricore’s pioneering work in real-time data and health testing through its platform, HealthTab™, which empowers pharmacies to support patient health outcome...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch